171 related articles for article (PubMed ID: 22285955)
1. Selective regression of cancer cells expressing a splicing variant of AIMP2 through targeted RNA replacement by trans-splicing ribozyme.
Won YS; Lee SW
J Biotechnol; 2012 Mar; 158(1-2):44-9. PubMed ID: 22285955
[TBL] [Abstract][Full Text] [Related]
2. Cancer-selective induction of cytotoxicity by tissue-specific expression of targeted trans-splicing ribozyme.
Song MS; Lee SW
FEBS Lett; 2006 Sep; 580(21):5033-43. PubMed ID: 16949075
[TBL] [Abstract][Full Text] [Related]
3. Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript.
Kwon BS; Jung HS; Song MS; Cho KS; Kim SC; Kimm K; Jeong JS; Kim IH; Lee SW
Mol Ther; 2005 Nov; 12(5):824-34. PubMed ID: 16040278
[TBL] [Abstract][Full Text] [Related]
4. Targeted retardation of hepatocarcinoma cells by specific replacement of alpha-fetoprotein RNA.
Won YS; Lee SW
J Biotechnol; 2007 May; 129(4):614-9. PubMed ID: 17360066
[TBL] [Abstract][Full Text] [Related]
5. Ribozyme-mediated selective killing of cancer cells expressing carcinoembryonic antigen RNA by targeted trans-splicing.
Jung HS; Lee SW
Biochem Biophys Res Commun; 2006 Oct; 349(2):556-63. PubMed ID: 16945335
[TBL] [Abstract][Full Text] [Related]
6. Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression.
Lee HS; Kim DG; Oh YS; Kwon NH; Lee JY; Kim D; Park SH; Song JH; Lee S; Han JM; Park BJ; Lee J; Kim S
Biochem J; 2013 Sep; 454(3):411-6. PubMed ID: 23815603
[TBL] [Abstract][Full Text] [Related]
7. Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo.
Song MS; Jeong JS; Ban G; Lee JH; Won YS; Cho KS; Kim IH; Lee SW
Cancer Gene Ther; 2009 Feb; 16(2):113-25. PubMed ID: 18758435
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesis.
Choi JW; Kim DG; Lee AE; Kim HR; Lee JY; Kwon NH; Shin YK; Hwang SK; Chang SH; Cho MH; Choi YL; Kim J; Oh SH; Kim B; Kim SY; Jeon HS; Park JY; Kang HP; Park BJ; Han JM; Kim S
PLoS Genet; 2011 Mar; 7(3):e1001351. PubMed ID: 21483803
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific gene delivery using RNA-targeting Tetrahymena group I intron.
Jung HS; Kwon BS; Lee SW
Biotechnol Lett; 2005 Apr; 27(8):567-74. PubMed ID: 15973491
[TBL] [Abstract][Full Text] [Related]
10. Gene expression responses in vivo by human telomerase reverse transcriptase (hTERT)-targeting trans-splicing ribozyme.
Song MS; Jeong JS; Cho KS; Lee SW
Exp Mol Med; 2007 Dec; 39(6):722-32. PubMed ID: 18160843
[TBL] [Abstract][Full Text] [Related]
11. Selective regression of cells expressing mouse cytoskeleton-associated protein 2 transcript by trans-splicing ribozyme.
Kim A; Ban G; Song MS; Bae CD; Park J; Lee SW
Oligonucleotides; 2007; 17(1):95-103. PubMed ID: 17461766
[TBL] [Abstract][Full Text] [Related]
12. Rapid detection of exon 2-deleted AIMP2 mutation as a potential biomarker for lung cancer by molecular beacons.
Jo SM; Kim Y; Jeong YS; Hee Oh Y; Park K; Kim HS
Biosens Bioelectron; 2013 Aug; 46():142-9. PubMed ID: 23537880
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of systemically delivered adenovirus harboring trans-splicing ribozyme in intrahepatic colon cancer mouse model.
Jeong JS; Lee SW; Hong SH; Lee YJ; Jung HI; Cho KS; Seo HH; Lee SJ; Park S; Song MS; Kim CM; Kim IH
Clin Cancer Res; 2008 Jan; 14(1):281-90. PubMed ID: 18172280
[TBL] [Abstract][Full Text] [Related]
14. Ratio of Autoantibodies of Tumor Suppressor AIMP2 and Its Oncogenic Variant Is Associated with Clinical Outcome in Lung Cancer.
Jung JY; Kim EY; Kim A; Chang J; Kwon NH; Moon Y; Kang EJ; Sung JS; Shim H; Kim S; Chang YS
J Cancer; 2017; 8(8):1347-1354. PubMed ID: 28638448
[TBL] [Abstract][Full Text] [Related]
15. In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells.
Hong SH; Jeong JS; Lee YJ; Jung HI; Cho KS; Kim CM; Kwon BS; Sullenger BA; Lee SW; Kim IH
Mol Ther; 2008 Jan; 16(1):74-80. PubMed ID: 17700543
[TBL] [Abstract][Full Text] [Related]
16. In vivo reprogramming of human telomerase reverse transcriptase (hTERT) by trans-splicing ribozyme to target tumor cells.
Lee SJ; Lee SW; Jeong JS; Kim IH
Methods Mol Biol; 2010; 629():307-21. PubMed ID: 20387158
[TBL] [Abstract][Full Text] [Related]
17. Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer.
Ku J; Kim R; Kim D; Kim D; Song S; Lee K; Lee N; Kim M; Yoon SS; Kwon NH; Kim S; Kim Y; Koh Y
Commun Biol; 2020 Oct; 3(1):630. PubMed ID: 33128014
[TBL] [Abstract][Full Text] [Related]
18. Use of tumor-targeting trans-splicing ribozyme for cancer treatment.
Lee SW; Jeong JS
Methods Mol Biol; 2014; 1103():83-95. PubMed ID: 24318888
[TBL] [Abstract][Full Text] [Related]
19. Molecular imaging of endogenous mRNA expression in a mouse tumor model by adenovirus harboring trans-splicing ribozyme.
Hong SH; Jeong JS; Lee YJ; Jung HI; Kim KT; Kim YH; Lee YS; Lee SW; Bae CD; Park J; Kim IH
FEBS Lett; 2007 Nov; 581(28):5396-400. PubMed ID: 17976379
[TBL] [Abstract][Full Text] [Related]
20. Discovery of benzodioxane analogues as lead candidates of AIMP2-DX2 inhibitors.
Lee B; Gyu Kim D; Mi Kim Y; Kim S; Choi I
Bioorg Med Chem Lett; 2022 Oct; 73():128889. PubMed ID: 35842206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
